Moreover, previous studies identified NAV3 as a putative tumor suppressor in cutaneous T-cell lymphoma and in the associated lung tumors (Karenko et al, 2005; Hahtola et al, 2008). Here, NAV3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.